MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.390
-0.040
-2.80%
After Hours: 1.350 -0.04 -2.88% 19:41 07/10 EDT
OPEN
1.390
PREV CLOSE
1.430
HIGH
1.430
LOW
1.360
VOLUME
194.14K
TURNOVER
--
52 WEEK HIGH
2.350
52 WEEK LOW
0.2800
MARKET CAP
20.22M
P/E (TTM)
-1.9886
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATHE stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.

EPS

ATHE News

More
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. 
Benzinga · 5d ago
35 Stocks Moving in Monday's Pre-Market Session
Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares rose 88.2% to $2.39 in pre-market trading after declining over 5% on Thursday.
Benzinga · 5d ago
66 Biggest Movers From Thursday
Gainers GEE Group, Inc. (NYSE: JOB) shares climbed 199.9% to close at $1.54 on Thursday after the company eliminated over $47 million in debt and mezzanine financing.
Benzinga · 5d ago
NUS, CPST, SOLO and MEIP among midday movers
Seeking Alpha - Article · 07/02 16:42
TTOO, MMLP, INO and BLNK among midday movers
Seeking Alpha - Article · 07/01 16:43
FDX, BYND among premarket gainers
Seeking Alpha - Article · 07/01 12:11
Why Alterity Therapeutics Stock Is Trading Higher Today
Alterity Therapeutics shares are trading higher on Tuesday after the company announced it received a development pathway from its meeting with the FDA for ATH434.
Benzinga · 06/30 19:49
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ATHE

Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
More

Webull offers kinds of Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ:ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.